Prospective Graduate Students / Postdocs
This faculty member is currently not looking for graduate students or Postdoctoral Fellows. Please do not contact the faculty member with any such requests.
Mads Daugaard
Associate Professor
Research Classification
Research Interests
Cancer Diagnosis and Detection
Cancer biology
Cancer diagnostics
Cancer therapy
Cell Signaling and Cancer
Cell Therapy of Cancer
Chemotherapy
DNA damage response pathways
glycobiology
Immunotherapy
Radiotherapy
Cell stress and Cancer
Cell stress signalling in cancer
Relevant Thesis-Based Degree Programs
Affiliations to Research Centres, Institutes & Clusters
Research Options
I am available and interested in collaborations (e.g. clusters, grants).
I am interested in and conduct interdisciplinary research.
Biography
Dr. Mads Daugaard is Head of the Molecular Pathology and Cell Imaging Unit, Senior Research Scientist at Vancouver Prostate Centre (VPC), and associate Professor at Department of Urologic Sciences, University of British Columbia (UBC). Daugaard operates in the translational cancer research space, integrating basic cancer discovery research with experimental therapeutic and diagnostic development in high-risk adult and childhood solid tumors. As part of his translational research focus, Daugaard has established the therapeutic development companies VAR2 Pharmaceuticals and OncoMal (2012), and the cancer diagnostics company VARCT Diagnostics (2017) to facilitate translation of his research towards the clinical arena. He is a co-PI of the VPC small-molecule drug development pipeline ADDUCT. Daugaard has attracted > $10M in federal and foundation support for his academic research programs and secured investments of >$10M for commercial development and translation of his research discoveries. He received the 2019 Robert J. Arceci Innovation Award from the St. Baldrick’s Foundation in 2019 and the Prostate Cancer Canada Rising Star Award in 2014.
Research Methodology
Recombinant proteins
biochemistry
molecular biology
Flow cytometry
Mass Spectrometry
CRISPR/Cas9 technology
Mouse models of cancer
Cancer cell line panels
bioinformatics
DNA and RNA Sequencing
Molecular pathology
Translational oncology
Publications
- Internalization and trafficking of CSPG-bound recombinant VAR2CSA lectins in cancer cells. (2022)
Scientific reports, - A Potential Role for HUWE1 in Modulating Cisplatin Sensitivity (2021)
Cells, - Alternative polyadenylation is a determinant of oncogenic Ras function. (2021)
Science advances, - Development of a bispecific immune engager using a recombinant malaria protein. (2021)
Cell death & disease, - HACE1 blocks HIF1α accumulation under hypoxia in a RAC1 dependent manner. (2021)
Oncogene, - NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity (2021)
Blood Cancer Discovery, 2 (6), 648--665 - Oncofetal Chondroitin Sulfate Is a Highly Expressed Therapeutic Target in Non-Small Cell Lung Cancer (2021)
Cancers, - Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing Sarcoma. (2021)
Cancer discovery, - A simple method for detecting oncofetal chondroitin sulfate glycosaminoglycans in bladder cancer urine (2020)
Cell Death Discovery, - An Affinity-Chromatography and Glycoproteomics Workflow to Profile the Chondroitin Sulfate Proteoglycans that interact with malarial VAR2CSA in the Placenta and in Cancer. (2020)
Glycobiology, - Cancer Cells Employ Nuclear Caspase-8 to Overcome the p53-Dependent G2/M Checkpoint through Cleavage of USP28. (2020)
Molecular cell, - Dianhydrogalactitol synergizes with topoisomerase poisons to overcome DNA repair activity in tumor cells. (2020)
Cell death & disease, - HACE1 prevents lung carcinogenesis via inhibition of RAC-family GTPases. (2020)
Cancer research, - Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. (2020)
Nature medicine, - Oncofetal Chondroitin Sulfate: A Putative Therapeutic Target in Adult and Pediatric Solid Tumors. (2020)
Cells, - Post-translational modifications in bladder cancer: Expanding the tumor target repertoire (2020)
Urologic Oncology: Seminars and Original Investigations, 38 (12), 858--866 - UV-induced DNA damage response in blood cells for cancer detection (2020)
Medical Devices and Sensors, n/a (n/a), e10146 - Androgen-regulated transcription of ESRP2 drives alternative splicing patterns in prostate cancer. (2019)
eLife, - BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. (2019)
Genome medicine, - Capture and Detection of Circulating Glioma Cells Using the Recombinant VAR2CSA Malaria Protein. (2019)
Cells, - Challenges and opportunities in exosome research-Perspectives from biology, engineering, and cancer therapy. (2019)
APL bioengineering, - Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma. (2019)
The American journal of surgical pathology, - Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Carcinoma. (2019)
The American journal of surgical pathology, - Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis. (2019)
Transfusion medicine reviews, - Calcium-sensing receptor (CaSR) promotes development of bone metastasis in renal cell carcinoma. (2018)
Oncotarget, - Dianhydrogalactitol induces replication-dependent DNA damage in tumor cells preferentially resolved by homologous recombination. (2018)
Cell Death & Disease, - Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer. (2018)
Molecular cancer therapeutics, - SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1. (2018)
EMBO molecular medicine, - The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent manner. (2018)
Nature communications, - An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer. (2017)
European urology, - Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. (2017)
Cancer, - Burkitt lymphoma expresses oncofetal chondroitin sulfate without being a reservoir for placental malaria sequestration. (2017)
International journal of cancer, - DRES-10. THE DISTINCT CYTOTOXIC MECHANISM OF DIANHYDROGALACTITOL (VAL-083) OVERCOMES CHEMORESISTANCE AND PROVIDES NEW OPPORTUNITIES FOR COMBINATION THERAPY IN THE TREATMENT OF GLIOBLASTOMA. (2017)
Neuro-Oncology, - Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis. (2017)
BMJ open, - Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer. (2017)
Nature Communications, - hace1 Influences zebrafish cardiac development via ROS-dependent mechanisms. (2017)
Developmental dynamics : an official publication of the American Association of Anatomists, - HGG-02. DIANHYDROGALACTITOL (VAL-083) OVERCOMES MGMT- AND P53-MEDIATED CHEMO-RESISTANCE AND DISPLAYS SYNERGY WITH TOPOISOMERASE INHIBITORS. (2017)
Neuro-oncology, - Identification of cancer-associated missense mutations in hace1 that impair cell growth control and Rac1 ubiquitylation. (2017)
Scientific reports, - P08.57 Distinct mechanism-of-action of dianhydrogalactitol (VAL-083) overcomes chemoresistance in glioblastoma. (2017)
Neuro-oncology, - PDTM-27. DIANHYDROGALACTITOL (VAL-083) OVERCOMES CHEMORESISTANCE IN PEDIATRIC MALIGNANT BRAIN TUMORS AND DISPLAYS SYNERGY WITH TOPOISOMERASE INHIBITORS. (2017)
Neuro-Oncology, - Hepatoma-derived growth factor-related protein 2 promotes DNA repair by homologous recombination. (2016)
Nucleic acids research, - Oncofetal Chondroitin Sulfate Glycosaminoglycans Are Key Players in Integrin Signaling and Tumor Cell Motility. (2016)
Molecular cancer research : MCR, - P08.47 Dianhydrogalactitol (VAL-083) causes bifunctional alkylation leading to irreparable DNA double-strand breaks, S/G2 phase cell-cycle arrest and tumor cell death in an MGMT independent manner offering a unique treatment paradigm for GBM. (2016)
Neuro-oncology, - Placental Sequestration of Plasmodium falciparum Malaria Parasites Is Mediated by the Interaction Between VAR2CSA and Chondroitin Sulfate A on Syndecan-1. (2016)
PLoS Pathogens, - Real-time and label free determination of ligand binding-kinetics to primary cancer tissue specimens; a novel tool for the assessment of biomarker targeting. (2016)
Sensing and Bio-Sensing Research, - Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation. (2016)
Molecular cancer therapeutics, - The Tumor Suppressor Hace1 Is a Critical Regulator of TNFR1-Mediated Cell Fate. (2016)
Cell reports, - Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. (2015)
Blood, - Loss of the tumor suppressor Hace1 leads to ROS-dependent glutamine addiction. (2015)
Oncogene, - Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein. (2015)
Cancer cell, - HACE1 reduces oxidative stress and mutant Huntingtin toxicity by promoting the NRF2 response. (2014)
Proceedings of the National Academy of Sciences of the United States of America, - Hace1 controls ROS generation of vertebrate Rac1-dependent NADPH oxidase complexes. (2013)
Nature communications, - The tumour suppressor HACE1 controls cell migration by regulating Rac1 degradation. (2013)
Oncogene, - ErbB2-driven breast cancer cell invasion depends on a complex signaling network activating myeloid zinc finger-1-dependent cathepsin B expression. (2012)
Molecular cell, - Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation. (2012)
Oncogene, - LEDGF (p75) promotes DNA-end resection and homologous recombination. (2012)
Nature structural & molecular biology, - Identification of small molecule inhibitors of phosphatidylinositol 3-kinase and autophagy. (2011)
The Journal of biological chemistry, - BAMLET activates a lysosomal cell death program in cancer cells. (2010)
Molecular cancer therapeutics, - Lens epithelium-derived growth factor is an Hsp70-2 regulated guardian of lysosomal stability in human cancer. (2007)
Cancer research, - The heat shock protein 70 family: Highly homologous proteins with overlapping and distinct functions. (2007)
FEBS letters, - Hsp70-2 is required for tumor cell growth and survival. (2005)
Cell cycle (Georgetown, Tex.), - Members of the heat-shock protein 70 family promote cancer cell growth by distinct mechanisms. (2005)
Genes & development,
Membership Status
Partner appointment
View explanation of statuses
Location
Vancouver General Hospital
Program Affiliations
Academic Unit(s)
If this is your researcher profile you can log in to the Faculty & Staff portal to update your details and provide recruitment preferences.